Superworth

Alnylam Pharmaceuticals price to free cash flow ALNY

Market value divided by free cash flow over the last twelve months, since 2024.

Today, Nov 3, 2026
26.7×
3-year median
110×
Against its 3-year history
1st
percentile: 0 is its lowest day, 100 its highest
3-year range
26.6× to 473×
Peer median
25.1×

Alnylam Pharmaceuticals' price to free cash flow is 26.7× as of Nov 3, 2026.

That is below its 3-year median of 110×, lower than on 99% of days in the last 3 years.

Over that time it ranged from 26.6× in Nov 2026 to 473× in Feb 2024.

The median for 10 biotech stocks of a similar size is 25.1×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far26.6×26.6×239×
2025239×237×273×
2024115×99.4×473×

Against its peers

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

CompanyPrice to free cash flow
ALNYAlnylam Pharmaceuticals26.7×
INCYIncyte12.7×
UTHRUnited Therapeutics23.7×
EXELExelixis14.8×
NBIXNeurocrine Biosciences17.0×
HALOHalozyme Therapeutics18.2×
TECHBIO-TECHNE43.3×
ONCBeOne Medicines30.2×
RGENRepligen87.2×
KRYSKrystal Biotech34.0×
REGNRegeneron Pharmaceuticals26.6×
Peer median25.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Alnylam Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.